CNPR FDA Regulations 5

Question 1

The Hatch-Waxman Act of 1984 created what important balance in pharmaceutical regulation?

Accepted Answer

Balance between encouraging generic drug competition and protecting brand-name drug innovation through exclusivity periods

Answer

The Hatch-Waxman Act simultaneously made generic drug approval easier via ANDAs while granting brand-name drugs market exclusivity periods to recoup R&D investment.

Question 2

Under FDA regulations, which of the following statements about comparative advertising claims is correct?

Accepted Answer

Comparative claims must be truthful, fairly balanced, and supported by substantial evidence

Answer

Comparative claims in pharmaceutical advertising are permitted but must be based on substantial evidence, presented fairly, and not mislead about the competitor product.

Question 3

What does the term 'substantial evidence' mean in the context of FDA drug approval for efficacy?

Accepted Answer

Evidence from adequate and well-controlled investigations demonstrating the drug's effectiveness

Answer

The FDA requires substantial evidence of efficacy, typically meaning data from two adequate and well-controlled clinical trials demonstrating the drug's claimed effects.

Question 4

A pharmaceutical sales representative receives a request from a physician asking for data on using a drug for a condition not in the approved labeling. What is the appropriate response?

Accepted Answer

Refer the request to medical affairs for an appropriate medical information response

Answer

Unsolicited off-label information requests should be referred to the company's Medical Affairs or Medical Information department, which can provide non-promotional scientific exchange.

Question 5

Under the Physician Payments Sunshine Act (Open Payments), pharmaceutical manufacturers must report transfers of value to physicians that exceed which threshold?

Accepted Answer

$10 per transfer or $100 annually

Answer

Manufacturers must report payments or transfers of value to physicians exceeding $10 per transfer or $100 in aggregate annually to CMS's Open Payments database.

(CNPR) Certified National Pharmaceutical Representative Practice Test

(CNPR) Certified National Pharmaceutical Representative Practice Test

CNPR FDA Regulations 5